azd2389

Liver Fibrosis

AstraZenecaPhase 2Active

BB

64/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 89/ 100

Competitive context

26 Active assets in the Liver Fibrosis cohort.

Asset / Sponsor	Phase	Rating
Entecavir Tanta University	Phase 4	BB
Peg-Intron Beth Israel Deaconess Medical Center	Phase 4	BB
COLCHICINUM Zagazig University	Phase 4	BB
Peg-Ifn Beijing Friendship Hospital	Phase 4	BB
Ribavirin ANRS, Emerging Infectious Diseases	Phase 3	BB

View all 50 →

Same molecule, other indications

azd2389 is also rated in:

cirrhosis of liverDormant

BB

Indicative ·

64 / 100

liver disorderDormant

CCC

Indicative ·

52 / 100

liver disorderDormant

CC

Indicative ·

47 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.